Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company, announced the issuance of U.S. Patent #12,601,803, titled “System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain.” The patent protects the company’s use of artificial intelligence (AI) to analyze magnetic resonance spectroscopy (MRS) data for assessing chronic low back pain, a condition affecting approximately 266 million people worldwide.
The patented technology underpins Aclarion’s cloud-based platform, Nociscan, which converts complex MRS spectral data into clinically actionable insights. By leveraging machine learning models, the platform extracts quantitative biomarkers from MRS data to generate standardized pain-related classifications. Additionally, the patent covers AI-based automated data quality controls that detect and exclude low-quality signals, such as excessive lipids or spectral artifacts, ensuring consistent and reproducible outputs across different imaging systems and clinical sites.
Brent Ness, Chief Executive Officer of Aclarion, said, “This patent strengthens the foundation of our platform by protecting how we leverage AI to transform complex spectroscopy data into meaningful, actionable information that physicians can integrate into everyday practice. By combining proprietary signal processing with machine learning, we are building a scalable and defensible approach to evaluating pain that has the potential to redefine how spine conditions are assessed while enabling highly efficient scaling and strong gross margin expansion.”
The patent expands Aclarion’s intellectual property portfolio to a total of 64 issued and pending patents worldwide. This robust IP foundation supports the company’s strategy to build a differentiated, software-driven platform in the chronic low back pain market. Clinical data has shown up to a 97% surgical success rate when all Nociscan-positive discs are treated, highlighting the platform’s potential to improve patient outcomes.
The issuance of this patent is expected to accelerate Aclarion’s ability to scale its operations and enhance gross margins by automating biomarker identification, expediting report generation, and reducing manual quality reviews. As the company continues to develop future versions of its platform, the patented AI workflow protections will be critical for maintaining a competitive edge in the underserved chronic low back pain market.
To read the patent, click here. For more information about Aclarion and Nociscan, visit www.aclarion.com.
